Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 02, 2004. The report details specific corporate actions regarding share transactions and director interests rather than providing a comprehensive financial performance update.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to a specific share repurchase transaction:
- Shares Purchased: 425,000 Ordinary shares.
- Purchase Price: 1,158.47 pence per share.
- Treasury Holdings: 48,978,000 shares held in Treasury following the transaction.
- Shares in Issue: 5,886,854,879 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares due to a buyback executed on November 02, 2004, authorized by shareholders at the Annual General Meeting on May 17, 2004. Additionally, the GSK Trust transferred 2,804 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Key Facts for Investor Verification
- Verify the total cost of the 425,000 share repurchase against the reported price of 1,158.47 pence.
- Confirm the updated total share count (5,886,854,879) and Treasury holdings (48,978,000) in subsequent filings.
- Note that three directors (Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe) hold indirect interests in the GSK Trust shares.
- Recognize that this filing does not contain quarterly or annual financial performance data.